Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEGEDINA vs conventional therapy in steroid-resistant acute graft-versus-host disease
2015-001360-19Phase 3Completed
- Sponsor
- Adienne
- Start
- Jul 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of begelomab in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by Adienne. Primary endpoints: Efficacy of BEGEDINA versus conventional therapy in steroid-resistant acute graft-versus-host disease and Overall survival up to Study Day 180. Started Jul 2015; status: completed.
02
Drugs
begelomab
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on 2015-001360-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001360-19.